GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (NAS:AADI) » Definitions » Cash Flow from Investing

Aadi Bioscience (Aadi Bioscience) Cash Flow from Investing : $77.43 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Aadi Bioscience spent $0.74 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $7.65 Mil on purchasing investments. It gained $18.94 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Aadi Bioscience gained $10.56 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Aadi Bioscience Cash Flow from Investing Historical Data

The historical data trend for Aadi Bioscience's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Cash Flow from Investing Chart

Aadi Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
- 25.15 -132.89 83.21

Aadi Bioscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.33 50.56 12.67 3.65 10.56

Aadi Bioscience Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Aadi Bioscience's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Aadi Bioscience's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $77.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aadi Bioscience  (NAS:AADI) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Aadi Bioscience's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.74 Mil. It means Aadi Bioscience spent $0.74 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Aadi Bioscience's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Aadi Bioscience gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Aadi Bioscience's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Aadi Bioscience spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Aadi Bioscience's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Aadi Bioscience gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Aadi Bioscience's purchase of investment for the three months ended in Mar. 2024 was $-7.65 Mil. It means Aadi Bioscience spent {stock_data.stock.currency_symbol}}7.65 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Aadi Bioscience's sale of investment for the three months ended in Mar. 2024 was $18.94 Mil. It means Aadi Bioscience gained $18.94 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Aadi Bioscience's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Aadi Bioscience paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Aadi Bioscience's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Aadi Bioscience paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Aadi Bioscience's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Aadi Bioscience paid $0.00 Mil for other investing activities.


Aadi Bioscience Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Aadi Bioscience (Aadi Bioscience) Business Description

Traded in Other Exchanges
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Executives
Neil Desai director, officer: See Remarks C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
David James Lennon director, officer: Chief Executive Officer C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Lorettta M Itri officer: Chief Medical Officer
Brendan Delaney officer: Chief Operating Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun director C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault officer: Chief Financial Officer
Behzad Aghazadeh director, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc director, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc director, other: See Remarks 110 GREEN STREET, SUITE 800, NEW YORK NY 10012